Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill ...

Researchers developed a way to directly reprogram human glial cells into PV interneurons without passing through a stem‑cell stage.

By editing thousands of genes in mouse stem cells, the scientists identified a list of over 300 that are crucial for neural differentiation.

Researchers are continuing to explore how the CXCL13-to-BAFF ratio can be used to advance precision medicine for people with multiple sclerosis.

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

A newly identified and rare genetic variant slows the growth of mutated blood stem cells and reduces the risk of leukemia.

Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...

The chip can simulate breathing and lung disease for an individual, holding promise for testing personalized treatments for tuberculosis.

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.